Supplemental Info from Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Supplemental Figure 1: PLX8394 does not alter CRAF or c-Src phosphorylation; Supplemental Figure 2. Treatment of xenograft-derived tumor pieces in an ex vivo explant system; Supplemental Figure 3: Patient sample extended data; Supplemental Figure 4: Parallel ex vivo dosing and homodimerization of vemurafenib and PLX8394 treatments; Supplemental Figure 5: PBRT characterization; Supplemental Figure 6: Targeting AKT and PDGFRβ in PBRT cell lines does not resensitize to PLX8394; Supplemental Figure 7: BRAF V600E splice variant analysis of PBRT cell lines and signaling and growth response of second-line therapies; Supplemental Methods.
Keywords